These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 24249419)
1. Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Pienta KJ; Walia G; Simons JW; Soule HR Prostate; 2014 Feb; 74(3):314-20. PubMed ID: 24249419 [TBL] [Abstract][Full Text] [Related]
2. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066 [TBL] [Abstract][Full Text] [Related]
3. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679 [TBL] [Abstract][Full Text] [Related]
4. Current management of advanced and castration resistant prostate cancer. Gomella LG; Petrylak DP; Shayegan B Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717 [TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
6. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
7. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Rizzo A; Mollica V; Rosellini M; Marchetti A; Ricci AD; Fiorentino M; Battelli N; Santoni M; Massari F Pathol Res Pract; 2021 Jun; 222():153440. PubMed ID: 33857854 [TBL] [Abstract][Full Text] [Related]
8. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
9. The 22nd annual prostate cancer foundation scientific retreat report. Miyahira AK; Simons JW; Soule HR Prostate; 2016 Sep; 76(12):1037-52. PubMed ID: 27272144 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488 [TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
12. Development and prevalence of castration-resistant prostate cancer subtypes. Vellky JE; Ricke WA Neoplasia; 2020 Nov; 22(11):566-575. PubMed ID: 32980775 [TBL] [Abstract][Full Text] [Related]
13. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Sharifi N; Kawasaki BT; Hurt EM; Farrar WL Cancer Biol Ther; 2006 Aug; 5(8):901-6. PubMed ID: 16855379 [TBL] [Abstract][Full Text] [Related]
14. Androgen pathway resistance in prostate cancer and therapeutic implications. Maughan BL; Antonarakis ES Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250 [TBL] [Abstract][Full Text] [Related]
15. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814 [TBL] [Abstract][Full Text] [Related]
18. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540 [TBL] [Abstract][Full Text] [Related]
19. Therapy escape mechanisms in the malignant prostate. Santer FR; Erb HH; McNeill RV Semin Cancer Biol; 2015 Dec; 35():133-44. PubMed ID: 26299608 [TBL] [Abstract][Full Text] [Related]
20. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]